Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Pharmalicensing Logo - Go to Home page
Save this technology
close
Save to Existing Project
Save to a New Project
PON1 as a Detoxification Agent: Improved Anti-Atherosclerotic Activities for the Prevention of Restenosis
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1475
The enzyme Paraoxonase 1 (PON1) resides on HDL in the blood. The levels of PON1 and its catalytic proficiency appear to have a major impact on susceptibility to...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

The enzyme Paraoxonase 1 (PON1) resides on HDL in the blood. The levels of PON1 and its catalytic proficiency appear to have a major impact on susceptibility to atherosclerosis, cardiac and vascular diseases, cholesterol reducing drugs and various toxins and pollutants, such as organophosphates (pesticides and nerve gases). However, when trying to use the human PON1 one encounters several problems, including its insolubility and the lack of recombinant PON variants that can be expressed and manipulated in bacteria.

Aims/Hypothesis

There is a need for an enzyme with improved anti-atherosclerotic and detoxifying activities.

Results

PON1 resides within the cholesterol-carrying particles HDL and exhibits a multitude of activities related to the metabolism of drugs, lipids and other molecules associated with atherosclerotic vascular and cardiac diseases. The outlined technology utilized directed evolution in the laboratory, which yielded a series of variants that are 50-200 fold more proficient than native PON1 in different physiologically relevant tasks

Conclusion

The current technology offers new, genetically-engineered PON1 variants that are expressed in a fully functional form, at multi-milligram quantities and unprecedented purity.

Relevance/Opportunity

Please enquire quoting reference no. 1475 regarding licensing or codevelopment partnerships.
GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2015
Technology Type MECHANISM
Phase of Development CLINICAL TRIALS
CORPORATION